author-photo

Yuki Ozaki

Fukushima Medical University

19

Papers

44

Citations

Citation Trend

Filter By

Papers (14) Sort By

Journal Conference Others

[Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].

2021 Gan to kagaku ryoho. Cancer & chemotherapy
Show All
- Source
- Cite
- Save
Citations (0)
Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using 125I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004)

2021 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (2)
Diffuse Cystic Metastases in the Lung after Nivolumab Treatment in a Patient with Non-Small Cell Lung Cancer: A Case Report.

2021 Case Reports in Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Our experience of lung resection in patients who decline blood transfusion for religious reasons

2021 The Japanese Journal of Thoracic and Cardiovascular Surgery
Show All
- Source
- Cite
- Save
Citations (0)
Tumor β‑catenin expression is associated with immune evasion in non‑small cell lung cancer with high tumor mutation burden

2021 Oncology Letters
Show All
- Source
- Cite
- Save
Citations (2)
The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study.

2021 Cancer Immunology, Immunotherapy
Show All
- Source
- Cite
- Save
Citations (0)
CTLA-4 Expression in Tumor-infiltrating Lymphocytes Is Irrelevant to PD-L1 Expression in NSCLC.

2021 Anticancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab.

2020 Thoracic Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Prognostic impact of serum transthyretin in patients with non‑small cell lung cancer

2019 Molecular and Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer

2019 Cancer Immunology, Immunotherapy
Show All
- Source
- Cite
- Save
Citations (20)